Johnson & Johnson has beefed up a pharma manufacturing plant in Cape Town, South Africa that makes consumer health products. Now it intends to beef up the workforce there.
In a move aimed at doubling the world's cholera vaccine supply, the World Health Organization has given its nod to South Korean's EuBiologics to provide vaccines under its prequalification program.
SAN FRANCISCO-- Sometimes, it can tough to be filter out what a company means from the little it says at the J.P. Morgan Healthcare Conference. So please, allow us to do the summarizing--and check back throughout the week for updates.
Israeli startup V-Wave raked in $28 million in Series B financing for its implantable device for heart failure, funds that will help the company as it ramps up marketing for its product and eyes key regulatory approvals to help it gain market share.
Johnson & Johnson fell short Monday in its final effort to escape a Risperdal marketing penalty in South Carolina. The U.S. Supreme Court declined to take up J&J's last appeal in the case, putting the company on the hook for a $124 million penalty.
Johnson & Johnson Innovation and JJDC, the innovation-focused arms of Johnson & Johnson, have co-led a $15 million financing for CartiHeal to back its cell-free, tissue-regenerating implant called Agili-C that has a CE mark. The implant is used for procedures in the knee, ankle and big toe that indicate a need for regeneration of cartilage and the underlying bone, in addition to reduction in pain and other related symptoms.
In the do-well-by-doing-good category, pharma companies and their agency partners are stepping up their public health projects in the developing world, and they're spotlighting some of those efforts at the United Nations this week.
Pharma giant Johnson & Johnson said it has licensed the rights to various liver treatments from a unit of Hong Kong-based Sino Biopharmaceutical that it hopes will help lead to a cure for chronic hepatitis B.
Johnson & Johnson has long been the top med tech R&D spender--with an estimated $1.7 billion spent on its diagnostics and medical device R&D in 2014. Now it's building a bridge specifically into the consumer-oriented health and wellness industry that spans both med tech and consumer products businesses. The accelerator will specifically target technologies that address nutrition, physical activity, stress and sleep as well as alcohol and smoking cessation.
Johnson & Johnson's latest spate of partnerships highlights its willingness to go anywhere necessary to find all the pieces it needs to create a therapeutic cocktail that can provide a functional cure for hepatitis B.